Echinacea

This is echinacea’s strongest indication, and it is still only moderate. The 2007 Lancet Infectious Diseases meta-analysis of 14 studies reported a 58% reduction in the odds of developing a cold (OR 0.42, 95% CI 0.25–0.71) and a 1.4-day shorter duration ^{2Reference 2Shah SA et al. · 2007Meta-analysisEvaluation of echinacea for the prevention and treatment of the common cold — meta-analysisView study →}, and a 2006 meta-analysis restricted to experimental rhinovirus inoculation found colds 55% more likely on placebo than on standardised extract (OR 1.55, 95% CI 1.02–2.36) ^{4Reference 4Schoop R et al. · 2006Meta-analysisEchinacea in the prevention of induced rhinovirus colds — meta-analysisView study →}. A 2019 systematic review found a preventive risk ratio of 0.78 (95% CI 0.68–0.88) — a real but modest effect ^{3Reference 3David S · 2019Meta-analysisEchinacea for the prevention and treatment of upper respiratory tract infections — systematic review and meta-analysisView study →}. The honesty check comes from Cochrane: across 24 double-blind trials in 4631 people, none of the individual prevention comparisons reached significance, though their pooled trend suggested a 10–20% relative risk reduction ^{1Reference 1Karsch-Völk M et al. · 2014Systematic reviewEchinacea for preventing and treating the common cold — systematic review (Cochrane)View study →}. In children, an E. purpurea fresh-plant alcoholic extract (Echinaforce Junior, 400 mg three times daily) prevented recurrent respiratory infections and cut antibiotic use ^{7Reference 7Ogal M et al. · 2021RCTEchinacea reduces antibiotic usage in children through respiratory tract infection prevention — randomized controlled trialView study →}, and a 2025 meta-analysis of 9 paediatric RCTs (n=3169) found reduced URTI incidence (RR 0.81) and markedly lower antibiotic use (RR 0.18) ^{8Reference 8Pham TP et al. · 2025Meta-analysisEfficacy and safety of Echinacea purpurea in treating upper respiratory infections and otitis media in children — systematic review and meta-analysisView study →}. Individual trials, however, remain inconsistent: an experimental rhinovirus-inoculation RCT (Sperber 2004, n=48) found no reduction in infection or clinical illness with E. purpurea prophylaxis ^{9Reference 9Sperber SJ et al. · 2004RCTEchinacea purpurea for prevention of experimental rhinovirus colds — randomized controlled trialView study →}, and a hospital-personnel prevention RCT (O’Neil 2008, n=90, 8 weeks) reported only a modest reduction in the frequency of URTI symptoms ^{10Reference 10O’Neil J et al. · 2008RCTEffects of echinacea on the frequency of upper respiratory tract symptoms — randomized, double-blind, placebo-controlled trialView study →}. Effects cluster around specific standardised pressed-juice and alcoholic extracts of aerial E. purpurea — not tea or generic capsules ^{1Reference 1Karsch-Völk M et al. · 2014Systematic reviewEchinacea for preventing and treating the common cold — systematic review (Cochrane)View study →}.

Gap: the preventive effect is small, inconsistent across products, and of debatable clinical relevance; no single preparation has been confirmed across independent groups at low risk of bias.

Immune activation is echinacea’s proposed mechanism for the respiratory-infection signal, and it is well demonstrated preclinically. Ethanolic extracts and isolated cichoric acid modulate macrophage function in vitro, lowering LPS-stimulated NF-κB, TNF-α and nitric oxide ^{16Reference 16Stevenson LM et al. · 2005In vitroModulation of macrophage immune responses by Echinacea — in vitroView study →}, while polysaccharide-enriched fractions do the opposite in resting cells — upregulating macrophage cytokine output through MAPK signalling and improving clearance of Listeria in mice ^{17Reference 17Sullivan AM et al. · 2008In vitroEchinacea-induced macrophage activation — in vitro and in vivo (mouse)View study →}. A 2024 mechanistic review catalogues enhancement of macrophage and natural-killer-cell activity, phagocytosis and cytokine production across the alkylamide, caffeic-acid-derivative and polysaccharide fractions ^{22Reference 22Ahmadi F et al. · 2024ReviewPhytochemistry, mechanisms, and preclinical studies of Echinacea extracts in modulating immune responses to bacterial and viral infections — reviewView study →}. The recurring theme is that echinacea is immunomodulatory — dampening inflammatory signalling in activated cells while priming resting innate immunity — rather than simply an “immune booster” ^{16,22Reference 16Stevenson LM et al. · 2005In vitroModulation of macrophage immune responses by Echinacea — in vitroView study →Reference 22Ahmadi F et al. · 2024ReviewPhytochemistry, mechanisms, and preclinical studies of Echinacea extracts in modulating immune responses to bacterial and viral infections — reviewView study →}.

Gap: these are cell-culture and rodent endpoints; no human trial links a measured immune change to a clinical infection outcome, and effects differ by fraction and preparation.

The most mechanistically satisfying story in the plant. The root alkylamides — lipophilic isobutylamides — are partial agonists at the cannabinoid CB2 receptor, giving echinacea a defined molecular anti-inflammatory pathway distinct from its immune-stimulant reputation ^{22Reference 22Ahmadi F et al. · 2024ReviewPhytochemistry, mechanisms, and preclinical studies of Echinacea extracts in modulating immune responses to bacterial and viral infections — reviewView study →}. This translated into the plant’s most rigorous non-respiratory human data: in a 2017 study combining in vitro work with randomised clinical trials, an alkylamide-rich E. purpurea extract cut poly(I:C)-induced IL-6 and IL-8 in keratinocytes and, as a topical cream, significantly reduced atopic-eczema severity (SCORAD) versus comparator while restoring epidermal ceramide and lipid-barrier content ^{14Reference 14Oláh A et al. · 2017RCTEchinacea purpurea-derived alkylamides exhibit potent anti-inflammatory effects and alleviate clinical symptoms of atopic eczema — randomized clinical trialsView study →}. Caffeic-acid derivatives contribute a separate NF-κB-suppressing action in macrophages ^{16Reference 16Stevenson LM et al. · 2005In vitroModulation of macrophage immune responses by Echinacea — in vitroView study →}.

Gap: the strong human evidence is topical and dermatological; systemic anti-inflammatory benefit from oral echinacea has not been demonstrated in a clinical endpoint.

Treatment — taking echinacea once symptoms start — draws on the same large trial base as prevention but scores far lower (band D, 40%) because the human results are largely null: null human efficacy data is weak support for the claim, even when the trials are numerous and well-powered. Cochrane found that of seven treatment trials reporting cold duration, only one beat placebo, and concluded echinacea has not been shown to help treat colds ^{1Reference 1Karsch-Völk M et al. · 2014Systematic reviewEchinacea for preventing and treating the common cold — systematic review (Cochrane)View study →}. The largest single treatment RCT (Barrett 2010, n=719, ~10 g dried root day 1) found only a non-significant ~0.5-day and 28-point severity trend, with the authors stating the results “do not support” a substantive effect ^{5Reference 5Barrett B et al. · 2010RCTEchinacea for treating the common cold — randomized controlled trialView study →}. In children (Taylor 2003, JAMA, n=407), E. purpurea did not reduce URTI duration or severity at all, and was associated with more rash (7.1% vs 2.7%, P=0.008) ^{6Reference 6Taylor JA et al. · 2003RCTEfficacy and safety of echinacea in treating upper respiratory tract infections in children — randomized controlled trialView study →}. The 2019 meta-analysis likewise found no effect on duration (mean difference −0.45 days, CI crossing zero) ^{3Reference 3David S · 2019Meta-analysisEchinacea for the prevention and treatment of upper respiratory tract infections — systematic review and meta-analysisView study →}. A 2025 paediatric meta-analysis did detect a small duration benefit (SMD −0.19) alongside a modest rise in mild adverse events ^{8Reference 8Pham TP et al. · 2025Meta-analysisEfficacy and safety of Echinacea purpurea in treating upper respiratory infections and otitis media in children — systematic review and meta-analysisView study →}.

Gap: the best-powered treatment trials are null; any duration benefit is fractions of a day and preparation-dependent, and does not justify treating an established cold.

Echinacea’s caffeic-acid derivatives — cichoric acid, echinacoside, caftaric acid and chlorogenic acid — are effective radical scavengers in vitro, and a purified E. purpurea polysaccharide reduced oxidative stress and protected hepatic tissue in a rodent CCl₄ model ^{23Reference 23Hou R et al. · 2020In vitroPolysaccharide from Echinacea purpurea reduces oxidant stress in vitro and in vivo — in vitro and rodent studyView study →}. Review-level work groups echinacea among antioxidant-and-antibacterial botanicals on the strength of this phenolic content ^{24Reference 24Sharifi-Rad M et al. · 2018ReviewEchinacea plants as antioxidant and antibacterial agents — reviewView study →}. The activity is real at the constituent level but is a general property of caffeic-acid-rich plants rather than something distinctive, and it has not been tied to any clinical antioxidant outcome in people.

Gap: constituent- and rodent-level only; no human antioxidant endpoint, and marker content varies widely by species and plant part.

An unexpected and preparation-specific signal. A standardised E. angustifolia root extract (40 mg twice daily, 7 days) lowered State-Trait Anxiety Inventory state-anxiety scores by ~11 points versus ~3 on placebo (P<0.01), with the effect persisting through washout ^{11Reference 11Haller J et al. · 2020RCTDouble-blind placebo-controlled trial of the anxiolytic effects of a standardized Echinacea extractView study →}. A separate 6-week RCT of the EP107 extract (n=108) found anxiety reductions that did not separate from placebo on the primary outcome, though secondary mood and wellbeing measures improved ^{12Reference 12Lopresti AL · 2021RCTAnxiety-relieving and mood-enhancing effects of Echinacea angustifolia (EP107) — randomised, double-blind, placebo-controlled studyView study →}. These build on animal work showing a narrow-dose anxiolytic effect in the elevated-plus-maze and social-interaction tests, comparable to chlordiazepoxide but without sedation, attributed to alkylamide activity at cannabinoid/behavioural targets ^{13Reference 13Haller J et al. · 2010The effect of Echinacea preparations in three laboratory tests of anxiety: comparison with chlordiazepoxide — animal studyView study →}. Both human trials use the same specific E. angustifolia preparation from essentially one research group.

Gap: small, single-preparation, largely single-group evidence with a null primary outcome in one of the two RCTs — promising but not yet replicated independently.

Separate from immune modulation, echinacea extracts show direct virucidal activity against enveloped viruses. A 2020 study found the E. purpurea preparation Echinaforce inactivated human coronavirus 229E, MERS-CoV, SARS-CoV-1 and SARS-CoV-2 on contact in vitro ^{15Reference 15Signer J et al. · 2020In vitroIn vitro virucidal activity of Echinaforce against coronaviruses, including 229E and SARS-CoV-2 — in vitroView study →}, consistent with a mechanistic literature describing membrane-level disruption of enveloped respiratory viruses ^{22Reference 22Ahmadi F et al. · 2024ReviewPhytochemistry, mechanisms, and preclinical studies of Echinacea extracts in modulating immune responses to bacterial and viral infections — reviewView study →}. This is a plausible contributor to the respiratory signal, but it is a test-tube endpoint: no placebo-controlled human trial has shown echinacea shortens or prevents a laboratory-confirmed viral infection through a demonstrated antiviral (as opposed to symptomatic or immune) mechanism.

Gap: entirely in vitro for the antiviral endpoint; virucidal concentrations and contact conditions in a dish do not establish clinical antiviral efficacy at achievable tissue exposures.

The weakest of the scored indications. Echinacea extracts show modest in vitro inhibition of respiratory-tract bacteria and appear in antioxidant/antibacterial screening reviews ^{24Reference 24Sharifi-Rad M et al. · 2018ReviewEchinacea plants as antioxidant and antibacterial agents — reviewView study →}, and mechanistic reviews note activity against respiratory pathogens as one strand of the anti-infective profile ^{22Reference 22Ahmadi F et al. · 2024ReviewPhytochemistry, mechanisms, and preclinical studies of Echinacea extracts in modulating immune responses to bacterial and viral infections — reviewView study →}. Crucially, this direct antibacterial action is not the explanation for the clinical URTI benefit — that tracks with immune modulation and prevention of secondary bacterial complications (e.g. reduced antibiotic need in children ^{7,8Reference 7Ogal M et al. · 2021RCTEchinacea reduces antibiotic usage in children through respiratory tract infection prevention — randomized controlled trialView study →Reference 8Pham TP et al. · 2025Meta-analysisEfficacy and safety of Echinacea purpurea in treating upper respiratory infections and otitis media in children — systematic review and meta-analysisView study →}), not with the plant behaving like an antibiotic.

Gap: in vitro potency is modest and species/preparation-dependent; there is no evidence echinacea acts as a clinically meaningful antibacterial in vivo.

Echinacea is well tolerated for short-term use, and the largest safety review found no serious harms attributable to it, with adverse events generally mild and comparable to placebo ^{18,3Reference 18Huntley AL et al. · 2005Systematic reviewThe safety of herbal medicinal products derived from Echinacea species — systematic reviewView study →Reference 3David S · 2019Meta-analysisEchinacea for the prevention and treatment of upper respiratory tract infections — systematic review and meta-analysisView study →}. The main real risk is allergic: because echinacea belongs to the daisy family (Asteraceae), people sensitised to ragweed, chrysanthemum, marigold or related plants can react, and rare anaphylaxis and asthma exacerbations have been reported ^{18Reference 18Huntley AL et al. · 2005Systematic reviewThe safety of herbal medicinal products derived from Echinacea species — systematic reviewView study →}. In one paediatric cold trial, echinacea caused significantly more skin rash than placebo (7.1% vs 2.7%) ^{6Reference 6Taylor JA et al. · 2003RCTEfficacy and safety of echinacea in treating upper respiratory tract infections in children — randomized controlled trialView study →}, and a 2025 paediatric meta-analysis noted a modest increase in mild adverse events ^{8Reference 8Pham TP et al. · 2025Meta-analysisEfficacy and safety of Echinacea purpurea in treating upper respiratory infections and otitis media in children — systematic review and meta-analysisView study →}. Because echinacea stimulates innate immunity, the German Commission E advises caution in progressive systemic and autoimmune disease, and a 2025 scoping review flags immunostimulatory supplements — echinacea among them — as a theoretical trigger for autoimmune-skin-disease flares ^{22Reference 22Ahmadi F et al. · 2024ReviewPhytochemistry, mechanisms, and preclinical studies of Echinacea extracts in modulating immune responses to bacterial and viral infections — reviewView study →}. Clinically important drug interactions appear unlikely: a controlled human study found no meaningful effect on CYP3A4, CYP1A2, CYP2D6 or CYP2E1 ^{19Reference 19Gurley BJ et al. · 2004RCTIn vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, saw palmetto — randomized crossover trialView study →}, echinacea did not alter warfarin’s anticoagulant effect despite a minor pharmacokinetic change ^{20Reference 20Abdul MIM et al. · 2010RCTPharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects — randomized crossover trialView study →}, and a herb–drug interaction meta-analysis did not flag echinacea as a perpetrator ^{21Reference 21Awortwe C et al. · 2019Meta-analysisInteraction of herbal products with prescribed medications — systematic review and meta-analysisView study →}.

Interactions have therefore been assessed directly and appear minimal; the remaining unknowns are long-term continuous use — traditionally echinacea is taken in short acute courses, not indefinitely — and pregnancy, covered below.